Cefuroxime axetil - Generic Drug Details

What are the generic sources for cefuroxime axetil and what is the scope of freedom to operate?

Cefuroxime axetil is the generic ingredient in two branded drugs marketed by Glaxosmithkline, Sun Pharm Inds Ltd, Alkem Labs Ltd, Anda Repository, Ani Pharms, Apotex, Aurobindo Pharma, Chartwell Rx, Fosun Pharma, Lupin, and Ranbaxy Labs Ltd, and is included in thirteen NDAs. Additional information is available in the individual branded drug profile pages.

There are thirty drug master file entries for cefuroxime axetil. Eighteen suppliers are listed for this compound.

Summary for cefuroxime axetil

US Patents:	0
Tradenames:	2
Applicants:	11
NDAs:	13
Drug Master File Entries:	30
Finished Product Suppliers / Packagers:	18
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	9
Patent Applications:	2,250
Drug Prices:	Drug price trends for cefuroxime axetil
What excipients (inactive ingredients) are in cefuroxime axetil?	cefuroxime axetil excipients list
DailyMed Link:	cefuroxime axetil at DailyMed

See drug prices for cefuroxime axetil

See drug sales revenues for cefuroxime axetil

Recent Clinical Trials for cefuroxime axetil

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hospital de Clinicas de Porto Alegre	PHASE4
Julio Ramirez	Early Phase 1
University of Louisville	Early Phase 1

See all cefuroxime axetil clinical trials

Pharmacology for cefuroxime axetil

Drug Class

Cephalosporin Antibacterial

Anatomical Therapeutic Chemical (ATC) Classes for cefuroxime axetil

J01DC	Second-generation cephalosporins
J01D	OTHER BETA-LACTAM ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for cefuroxime axetil

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	CEFUROXIME AXETIL	cefuroxime axetil	TABLET;ORAL	065166-002	Jul 29, 2005	AB	RX	No	No
Aurobindo Pharma	CEFUROXIME AXETIL	cefuroxime axetil	TABLET;ORAL	065308-001	Mar 29, 2006	AB	RX	No	No
Alkem Labs Ltd	CEFUROXIME AXETIL	cefuroxime axetil	TABLET;ORAL	065496-001	Jun 7, 2010	AB	RX	No	No

CEFUROXIME AXETIL: Market Dynamics and Financial Trajectory

Last updated: February 20, 2026

What is the current global market size and growth rate for cefuroxime axetil?

Cefuroxime axetil, a second-generation cephalosporin antibiotic, is used primarily for respiratory, urinary tract, and skin infections. The global antibiotic market was valued at approximately $55 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 3.8% from 2022 to 2027. Cefuroxime axetil accounts for roughly 4% of the second-generation cephalosporins segment.

In 2022, estimates place global cefuroxime axetil sales at around $2.2 billion, with North America contributing approximately 50%, Europe 25%, and the remaining 25% split across Asia-Pacific, Latin America, and Middle East/Africa. The high prevalence of respiratory infections and rising antibiotic resistance drive the segment's growth.

How do patent durations and generic competition influence the market?

Cefuroxime axetil was initially introduced in the 1990s. Multiple patents expired by 2010, leading to widespread generic manufacturing. Generic versions now comprise over 80% of global sales, exerting downward pressure on prices.

Market entry of generics correlates with a 40–50% reduction in average selling prices (ASPs). Major players like GlaxoSmithKline (original patent holder), Teva, Sandoz, and Mylan dominate the generic market. Patent protections differ by country, with some extending exclusive rights until 2025, notably in jurisdictions with supplementary patents.

This patent landscape encourages generic proliferation but also results in intense price competition, reducing profit margins for innovator companies.

What are key drivers and barriers affecting market expansion?

Drivers:

• Rising antibiotic resistance prompts increased use of second-generation cephalosporins.
• Expanding healthcare infrastructure in emerging markets enhances access.
• Growing awareness and diagnosis rates of bacterial infections.

Barriers:

• Stringent regulatory approvals delay new formulations.
• High antibiotic resistance limits efficacy, compelling the search for alternatives.
• Concerns over antibiotic stewardship and resistance curb overprescription.

How are pricing and reimbursement policies impacting revenues?

Price negotiation and reimbursement frameworks vary across regions. In the US, Centers for Medicare & Medicaid Services (CMS) and private payers influence pricing, with generic versions being significantly cheaper. In Europe, national health systems tend to negotiate drug prices, with discounts of up to 20–30% for generics.

Reimbursement policies favor cost-effectiveness, favoring generics, which translates into limited revenue for original branded formulations. Pharmaceutical companies derive higher margins from branded formulations with differentiated features, often limited in the case of cefuroxime axetil due to limited innovation.

What are potential future revenue streams and market opportunities?

• New formulations: Extended-release, pediatric, or combination formulations can command premium prices.
• Regional expansion: Growth prospects remain high in Asian markets with increasing healthcare access.
• Policy-driven demand: European health policies favor generic use, but developing countries still show a preference for branded drugs.

Projected revenues for next five years are expected to decline marginally due to extensive generics. However, niche markets such as hospitals and specialty clinics may sustain higher margins.

Which companies are leading in cefuroxime axetil production?

Company	Market Share	Key Developments	Patent Status
GlaxoSmithKline	Original producer	Patent expiration in 2010; now generic dominant	Dissolved patent, 2010 onward
Teva Pharmaceuticals	25% (generic)	Large production capacity; broad geographic reach	No patent restrictions
Sandoz	15%	Focus on developing markets	No patent restrictions
Mylan	10%	Diversified antibiotic portfolio	No patent restrictions

How do regional regulatory policies influence market access?

Regulatory approval processes influence the pace at which new markets become accessible. The US Food and Drug Administration (FDA) permits generic approval based on bioequivalence without extensive clinical trials, expediting market access but maintaining price pressures. European Medicines Agency (EMA) follows similar protocols with rigorous quality standards.

Emerging markets like India and China have less restrictive regulatory pathways, facilitating faster entry but raising concerns over quality assurance. These policies influence pricing strategy and market penetration timelines.

What are the key risks and uncertainties?

• Development of antibiotic resistance diminishes clinical efficacy.
• Potential for regulatory tightening, especially regarding antibiotic stewardship.
• Price erosion from generic competition limits revenue growth.
• Supply chain disruptions and raw material shortages can impact production volumes.

Summary of financial outlook

Year	Estimated Revenue	Key Factors
2022	~$2.2 billion	High generic penetration; price pressures
2023–2027	Slight decline expected	Continued commoditization; patent expiries

Market stabilization with limited growth potential; focus shifts to process efficiency and niche applications.

Key Takeaways

• The cefuroxime axetil market has matured post-patent expiry, dominated by generics.
• Revenue growth is constrained by pricing pressures and widespread generic competition.
• Opportunities arise in new formulations, regional market expansion, and hospital sectors.
• Pricing policies favor generics, reducing profitability for branded manufacturers.
• Antibiotic resistance and regulatory policies present ongoing risks.

FAQs

1. What is the primary therapeutic use of cefuroxime axetil? It treats respiratory, urinary tract, and skin infections caused by susceptible bacteria.

2. How has patent expiration affected the market? Patent expiries led to increased generic competition, lowering prices and profit margins.

3. Are there innovations expected to extend cefuroxime axetil’s market life? Yes; formulations such as extended-release or combination pills may provide niche opportunities.

4. Which region shows the highest growth potential? Asia-Pacific exhibits high prospects due to expanding healthcare infrastructure and increasing infection rates.

5. What are the main challenges facing manufacturers? Antibiotic resistance, regulatory constraints, and price erosion from generics.

---

References

[1] Grand View Research. (2022). Antibiotics Market Size, Share & Trends Analysis Report.
[2] IQVIA. (2022). Global Antibiotics Market Data.
[3] U.S. Food and Drug Administration. (2022). Bioequivalence Guidance.
[4] European Medicines Agency. (2022). Market Authorization Procedures for Generics.
[5] World Health Organization. (2022). Antibiotic Resistance Surveillance Reports.